• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system.

作者信息

Mellett L B

出版信息

Cancer Treat Rep. 1977 Jul;61(4):527-31.

PMID:884690
Abstract

The blood-brain barrier is not as rigid or as formidable as once believed. When experimental tumors of the central nervous system (CNS) and tumors of non-CNS origin are implanted intracerebrally (ic), they will grow and kill the host. It was once thought that only a few select agents, such as the nitrosoureas, were capable of crossing the blood-brain barrier and inhibiting tumor growth. There are now considerable data available which indicate that a variety of agents such as cytosine arabinoside, methotrexate, 6-mercaptopurine, 5-fluorouracil, procarbazine, melphalan, and cyclophosphamide, as well as the nitrosoureas, may significantly influence the growth rate of experimentally implanted ic tumors. A number of physicochemical factors may influence the penetration of the blood-brain barrier. These include pKa values, log-P values, and molecular size. Brain-level measurements indicate that most drugs have some accessibility to the CNS. Maximal effects against sensitive, ic implanted tumors are attained through maximal scheduling. Effective drug combinations should be sought to further enhance antitumor effects in the CNS.

摘要

相似文献

1
Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system.
Cancer Treat Rep. 1977 Jul;61(4):527-31.
2
Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain.
Cancer Res. 1991 Apr 15;51(8):1979-83.
3
Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.使用右丙亚胺挽救拓扑异构酶II,联合超致死剂量的依托泊苷和替尼泊苷,改善对脑肿瘤的靶向治疗。
Clin Cancer Res. 1998 Jun;4(6):1367-73.
4
Drug delivery to brain tumours: challenges and progress.药物递送至脑肿瘤:挑战与进展。
Expert Opin Drug Deliv. 2006 Jul;3(4):499-509. doi: 10.1517/17425247.3.4.499.
5
Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier.
Cancer Res. 1985 Jun;45(6):2827-33.
6
The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?抗癌药物通过血脑屏障的靶向递送:药物还是药物纳米颗粒的化学修饰?
Drug Discov Today. 2008 Dec;13(23-24):1099-106. doi: 10.1016/j.drudis.2008.09.005. Epub 2008 Oct 22.
7
[The blood-brain barrier: implications for chemotherapy in brain tumors].[血脑屏障:对脑肿瘤化疗的影响]
Pathol Biol (Paris). 1991 Oct;39(8):789-95.
8
Chemotherapy delivery issues in central nervous system malignancy: a reality check.中枢神经系统恶性肿瘤的化疗给药问题:现实审视
J Clin Oncol. 2007 Jun 1;25(16):2295-305. doi: 10.1200/JCO.2006.09.9861.
9
Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.通过动脉内输注和破坏血脑屏障增强恶性脑肿瘤的化疗给药:舍布鲁克的经验。
Cancer. 2005 Jun 15;103(12):2606-15. doi: 10.1002/cncr.21112.
10
Blood-brain barrier and chemotherapeutic treatment of brain tumors.血脑屏障与脑肿瘤的化疗治疗
Expert Rev Neurother. 2006 Aug;6(8):1199-209. doi: 10.1586/14737175.6.8.1199.

引用本文的文献

1
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.癌性脑膜炎:实体瘤的软脑膜转移
Surg Neurol Int. 2013 May 2;4(Suppl 4):S265-88. doi: 10.4103/2152-7806.111304. Print 2013.
2
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.异质性血脑屏障通透性决定乳腺癌实验性脑转移的药物疗效。
Clin Cancer Res. 2010 Dec 1;16(23):5664-78. doi: 10.1158/1078-0432.CCR-10-1564. Epub 2010 Sep 9.
3
Leptomeningeal metastases from solid malignancy: a review.
实体恶性肿瘤的软脑膜转移:综述
J Neurooncol. 2005 Oct;75(1):85-99. doi: 10.1007/s11060-004-8101-x.
4
Current options for the treatment of neoplastic meningitis.目前治疗肿瘤性脑膜炎的方法。
J Neurooncol. 2002 Oct;60(1):79-88. doi: 10.1023/a:1020200317464.
5
Pharmacologic strategies for the treatment of meningeal malignancy.治疗脑膜恶性肿瘤的药理学策略。
Invest New Drugs. 1996;14(1):69-85. doi: 10.1007/BF00173684.
6
A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.血脑屏障在人类脑肿瘤化疗中作用的批判性分析
J Neurooncol. 1994;20(2):121-39. doi: 10.1007/BF01052723.
7
The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.
J Neurooncol. 1983;1(3):219-24. doi: 10.1007/BF00165606.
8
Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).2,5-二氮丙啶基3,6-双(乙氧羰基氨基)-1,4-苯醌(AZQ,NSC-182986)的脑内渗透及组织分布
J Neurooncol. 1983;1(1):15-9. doi: 10.1007/BF00153636.
9
Blood-brain barrier integrity and host responses in experimental metastatic brain tumours.实验性转移性脑肿瘤中的血脑屏障完整性与宿主反应
Clin Exp Metastasis. 1983 Jul-Sep;1(3):229-46. doi: 10.1007/BF00736407.
10
A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
J Neurooncol. 1984;2(1):13-7. doi: 10.1007/BF00165153.